LungLife AI, INC - Block listing Interim Review
LungLife AI, Inc.
(the "Company" or "LungLife")
Block Admission Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
|
Name of Company: |
LungLife AI, Inc. |
|||
|
Name of scheme: |
1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan |
|||
|
Number and class of securities originally admitted: |
1,356,139 common shares of US |
|||
|
Date of admission: |
|
|||
|
Period of return: |
From: |
|
To: |
|
|
Balance of unallotted securities under scheme(s) from previous return: |
1. 475,583 2. 201,374 3. 673,990 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
1. NIL 2. NIL 3. NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period: |
1. NIL 2. NIL 3. NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period : |
1. 475,583 2. 201,374 3. 673,990 |
|||
|
Total number of securities in issue at the end of the period |
30,658,603 |
|||
|
Name of contact: |
|
|
Telephone number of contact: |
+44 (0)20 7933 8780 |
For further information please contact:
|
LungLife AI, Inc. |
||
|
|
||
|
|
|
|
|
|
|
|
|
Allenby Capital Limited Nominated Adviser and Joint Broker |
Tel: +44 (0)20 3328 5656
|
|
|
|
|
|
|
Goodbody (Joint Broker) |
Tel: +44 (0) 20 3841 6202 |
|
|
|
|
|
|
|
|
|
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.
Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE